Physician profile
Yan Jiang
NPI 1265812747
$2,586.34
in general payments reported to CMS, 2019-2025
34 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.43 · 2022: $466 · 2023: $338 · 2024: $704 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.23 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $324.95 | 2023-2025 | Imfinzi |
| Seagen INC. | $284.90 | 2022-2023 | |
| Incyte Corporation | $272.65 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $272.06 | 2023-2025 | Opdivo |
| Pfizer INC. | $269.41 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $172.13 | 2019-2025 | |
| Daiichi Sankyo INC. | $96.46 | 2024-2025 | Enhertu, Injectafer |
| Karyopharm Therapeutics INC. | $87.10 | 2022 | |
| Merck Sharp & Dohme LLC | $62.23 | 2024-2025 | Keytruda, Welireg |
| Genzyme Corporation | $61.33 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.27 | 2024-2025 | |
| Genentech USA, INC. | $54.94 | 2019-2025 | Tecentriq Hybreza, Itovebi |
| Lilly USA, LLC | $51.02 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $49.93 | 2019-2024 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $37.18 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $33.42 | 2024-2025 | Reblozyl |
| Janssen Biotech, INC. | $32.72 | 2024-2025 | Rybrevant, Talvey, Tecvayli |
| Astellas Pharma US INC | $32.05 | 2024-2025 | Padcev, Xtandi |
| Alexion Pharmaceuticals, INC. | $31.71 | 2025 | Ultomiris |
| Pharmaessentia USA Corporation | $29.17 | 2025 | Besremi |
| Eisai INC. | $24.27 | 2023 | |
| Beone Medicines USA, INC. | $23.92 | 2025 | Tevimbra |
| Tersera Therapeutics LLC | $21.16 | 2023 | Zoladex |
| Emd Serono, INC. | $21.05 | 2024 | |
| Accord Healthcare, INC. | $20.97 | 2025 | |
| Stemline Therapeutics INC. | $20.62 | 2023 | Orserdu |
| Adaptive Biotechnologies Corporation | $19.90 | 2025 | Clonoseq |
| Boston Scientific Corporation | $19.08 | 2024 | Watchman Flx |
| Abbvie INC. | $18.82 | 2024 | |
| Gilead Sciences, INC. | $18.65 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $17.79 | 2024 | Libtayo |
| Sun Pharmaceutical Industries INC. | $17.38 | 2023 | Yonsa, Odomzo |
| Azurity Pharmaceuticals, INC. | $15.06 | 2024 | Vivimusta |
| Array Biopharma INC | $13.04 | 2025 | Mektovi, Tukysa, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.